Dr. Stephanie Plassmann, Senior Expert in Non-Clinical Drug DevelopmentThe most decisive elements of drug development take shape long before a study appears on a Gantt chart. They sit in the scientific choices and drug development strategies. Based on these parts, operational factors such as dose-selection logic and study designs determine whether nonclinical evidence will hold up once regulators begin asking tough questions. Taken together, very early decisions set the trajectory of a molecule long before dosing begins and often determine how smoothly a program moves towards first-in-human readiness.
Getting those decisions right is why sponsors turn to PreClinical Safety (PCS) Consultants Ltd. Formed by project toxicology leaders trained from scratch in pharmaceutical industry in a GLP environment, including hands-on experience as study directors and laboratory heads, PCS understands that nonclinical development is a continuous process integrated into drug development rather than a sequence of isolated tasks.
The team’s professional background adds significant value. Beginning their careers in GLP environments taught them early on how scientific decisions, operational realities and regulatory expectations must work together for a program to succeed. Their work connects all the areas that shape nonclinical development.
“Our roots matter,” says Dr. Stephanie Plassmann, senior expert in nonclinical drug development at PCS. “We were trained to understand how each of our decisions carries weight when it reaches regulators. Our ability, based on expertise and experience, to combine hands-on execution and strategic reasoning is what gives our contribution its strength.”
For instance, contract research organisations (CRO) bring deep operational knowledge needed to run studies. Sponsors carry the scientific and strategic intent behind the molecule. Regulators examine the same data through the lens of patient safety, which is the guiding principle of the risk-benefit analysis for any given drug in development. The PCS team can bring these perspectives back into a single line of reasoning where they were disconnected, enabling programs to move forward on solid ground and prepare for clinical studies from first-in-human dosing to marketing authorisation. PCS may run integrated non-clinical study programs as a fully operational team, or take over selected parts of the process, covering strategic, operational and regulatory aspects, tailored to the specific needs of the client.
Designing Studies that Answer the Right Questions
How does correct dose selection influence regulatory readiness?
In toxicology, one of the most important pivot points is correct dosage selection. When dose levels fall below the needed range, the safety profile cannot be robustly investigated, and the most relevant information cannot be established comprehensively. Binding global guidelines clearly define the questions any safety program must answer: What are the target organ systems of toxicity? Which adverse findings were seen, how severe were these, can the program move into the clinical phase at all, and if so, what parameters can be monitored clinically to ascertain patient safety? And last not least, the pivot point in humans is dosage again: which dosage can be used to start with, how can dosages be safely increased, and up to which level? In the end, for a drug to be approved, the key question to be answered is: Can efficacious dosages be safely administered in human patients? If the answer is no, the drug in question will never reach the market.
We want to get a medication to the patient in need in the shortest possible time, but this objective must be achieved at the highest possible quality standards.
But dosage is only one example of a deeper issue. PCS sees analogue patterns across endpoints, sampling windows and recovery phases. Endpoints that later guide clinical monitoring can be missing if toxicology was not fully aligned with the right clinical plan. And decisions must be made upfront, since for example, recovery can only be studied when this endpoint was included from the beginning to demonstrate whether findings actually reverse once dosing stops.
PCS addresses these challenges by aligning the full strategy well in advance of a study reaching a CRO. The team begins by examining the molecule itself, including its mechanism, the clinical condition to treat and the patient population. This anchors every decision that follows. The first step must be to develop a sound non-clinical development strategy. From there, robust operational implementation is key, including the selection of the best CRO partners to run the studies. The overall aim is to arrive at a robust risk-benefit evaluation at each step of the way as basis for well-grounded decision-making. When considering dosage selection in the safety context, the dose ranges ideally are set to reach the maximum that can be tolerated, helping sponsors gain insight rather than leaving them uncertain when dose levels are too low. Blood sampling is timed to show how exposures correlate with effects to provide context. Endpoints are selected for their clinical relevance, and recovery phases are built in to indicate how quickly findings resolve and how monitoring should be continued. These results are continuously assessed with respect to the exposures required to achieve the pharmacologically desired effect, which in the end determines efficacy in the patient.
This level of clarity prevents repeating studies that slows down many programs. It matters even more in therapies for severe or life-limiting diseases, where unclear findings hinder progress for patients with limited treatment options.
Knowing the logic behind these types of questions enables PCS to anticipate them. The team members have actively contributed over the last decades to key scientific discussions that shaped modern standards such as for juvenile and reproductive and developmental toxicity, safety pharmacology and first-in-human readiness. They have served on advisory boards, joined working teams and trained fellow scientists through voluntary engagement in non-profit groups, gaining a close view of how regulators weigh evidence and where they look when something is unclear.
“We want to get a medication to the patient in need in the shortest possible time, but this objective must be achieved at the highest possible quality standards,” notes Stephanie.
That value shapes PCS’ role. It turns testing strategies by sound operational implementation into an opportunity for the sponsor—a chance to build a program that is not only technically correct but clinically meaningful and regulator-ready.
The Regulatory Lens that Sponsors Rely On
How does regulatory reasoning shape nonclinical program coherence?
When design aligns with how regulatory agencies interpret evidence, progress becomes cumulative. Each thoughtful decision strengthens the next, and a coherent program takes shape.
PCS can create that coherence because it goes beyond guidelines by critical thinking and reinforces the scientific principles on which they are based, as this is what regulators expect. It knows that regulators aim to determine if the scientific reasoning is sound, if the exposure margins are reasonable for the proposed clinical dose and if organ-specific findings have been interpreted within the right clinical context.
-
Engagements are tailored to each organisation's specific context and intended to help teams sustain coherent decision-making as programs progress.
Knowing the logic behind these types of questions enables PCS to anticipate them. The team members have actively contributed over the last decades to key scientific discussions that shaped modern standards such as for juvenile and reproductive and developmental toxicity, safety pharmacology and first-in-human readiness. They have served on advisory boards, joined working teams and trained fellow scientists through voluntary engagement in non-profit groups, gaining a close view of how regulators weigh evidence and where they look when something is unclear.
“What sponsors often need is not more data, but stronger reasoning behind the data. When the scientific justification is solid from start to finish, regulators can follow the logic and understand the risks and opportunities of a drug in development. The ultimate aim is that the medication must work while being safe,” says Stephanie.
Making Sense of the Advanced Toxicology Modalities
Why is expert judgment essential in advanced toxicology modalities?
As programs adopt more complex toxicology modalities, the need for the right judgment becomes even more important. Guidelines provide a framework, but they do not address timing, sequencing and interpretation details that make or break these studies.
Juvenile toxicity, for example, requires precise alignment between dosing windows and developmental stages. Small timing errors can render them unusable for clinical justification.
Reproductive and developmental toxicity studies follow a similar logic, with biological events determining when exposure is meaningful and how outcomes should be interpreted. Some areas such as orphan diseases, often affecting the CNS, or oncology programs present specific challenges. Scientific progress often outpaces existing regulatory guidelines, making practical experience essential for sound judgement. Guidelines in new fields may follow once a practical standard has developed.
PCS approaches these specialised areas by grounding every decision in accumulated evidence established in the overarching strategic context. Decades of working inside this strongly regulated environment have taught the team how to read the signals that matter, especially in modalities where small shifts can change the entire interpretation. In these programs, success depends on the correct procedural execution originating from the kind of judgment that comes from designing, interpreting and defending studies in the integrated developmental context.
A Partner for Every Stage of Development
Every development cycle is different, and PCS adapts its role to meet the demands of each situation. For university groups, early-stage biotechs and smaller organisations, it often becomes the non-clinical function they do not yet have, shaping study programs, implementing them operationally and helping them prepare for regulatory submissions. Mid-sized and large pharmaceutical companies turn to the team when they need independent judgment or additional expertise. And investors rely on PCS for due diligence, utilising the firm’s expertise to assess if a program’s foundation is as robust as it appears before capital moves.
Across all these scenarios, the common thread is not size but the need for decisions grounded in scientific reasoning and regulatory practicality. PCS brings that steadiness to programs at any stage, helping organisations move forward with clarity instead of guesswork.
PCS may serve as a scientific and strategic advisor, a program architect or an embedded nonclinical development team. Clients determine how and where the firm integrates, whether that means full ownership of a program, targeted scientific oversight or independent expert review at critical decision points.
Guidance that Grows with the Program
Beyond direct project support, the firm works along with internal teams to align judgment across scientific, clinical and regulatory domains. As development environments evolve, familiar decisions increasingly need to be made in more integrated ways. PCS supports this alignment by examining how study designs are assessed, how emerging signals are interpreted and how lines of scientific logic are articulated for regulatory discussions.
These engagements are tailored to each organisation's specific context and intended to help teams sustain coherent decision-making as programs progress.
That coherence is PCS’s signature contribution. It reflects the firm’s role as an integrated drug development partner, where scientific design, operational execution and regulatory reasoning are treated as a single discipline. For companies navigating a complex development landscape, this integration is the difference between moving forward in the dark and advancing with clarity.
Closing the Gap Between CRO Execution and Regulatory Strategy in Preclinical Development
Pharmaceutical development programs rarely fail because a toxicology study was conducted incorrectly at the technical level. They falter when study design, dose selection and regulatory positioning are misaligned from the outset. Executives responsible for pharmaceutical advisory services must therefore look beyond whether a contract research organisation can execute studies to scientific standards and examine whether the overall nonclinical strategy truly supports clinical and regulatory objectives.
CROs contribute essential expertise in running studies under GLP conditions. They establish appropriate group sizes, standard endpoints, pathology assessments and pharmacokinetic evaluations. They rely on trained personnel who can interpret clinical observations in animals, distinguish adaptive from adverse findings and maintain reproducibility. This technical foundation is indispensable. Yet it does not automatically translate into strategic alignment with evolving ICH guidance or the specific regulatory pathway of a compound.
The gap often appears in dose selection and program planning. Guidance such as ICH M3(R2) outlines principles for nonclinical safety studies that support human trials, including the expectation to characterise toxicity at sufficiently high exposure levels and to identify potential target organs. Determining the maximum tolerated dose, or justifying alternative approaches when that concept cannot be applied, requires deep scientific judgment and regulatory interpretation. Sponsors, particularly smaller organizations, may lack hands-on experience designing such studies. CROs may defer dose decisions to sponsors or focus on execution rather than regulatory rationale. The result can be pivotal studies that technically meet standards yet fail to satisfy regulators, leading to repeat studies or delays at critical milestones.
Another frequent weakness lies in forward planning. Many endpoints in toxicology programs cannot be added retrospectively. Recovery cohorts, additional blood sampling schedules or specific histopathological evaluations must be incorporated at the design stage.
These elements are directly tied to how clinical monitoring parameters will later be defined. Nonclinical programs are not isolated exercises; their primary purpose is to inform safe dose titration, identify target organ systems and guide monitoring strategies in human trials. When that linkage is not clearly articulated, regulatory interactions become more difficult and credibility can erode.
Pharmaceutical advisory firms are therefore judged on their ability to connect hands-on GLP experience with strategic regulatory foresight. PreClinical Safety Consultants centers its work precisely in this junction. Its team has directed studies within GLP environments, participated in inspections and managed development programs at a strategic level. That dual perspective allows it to evaluate not only whether a study can be run competently but whether it should be structured differently to answer the regulatory question at hand.
It supports sponsors in selecting specific CRO test sites rather than relying on brand reputation alone, recognising that capabilities vary across facilities and study types. It conducts due diligence for complex or unprecedented programs, including advanced therapeutic medicinal products where established pathways are limited. It advises on dose level selection grounded in thorough review of existing data and interpretation of ICH principles, reducing the likelihood that regulators will later question exposure margins or the absence of target organ toxicity.
Organisations that involve such advisory support early in development are positioned to design pivotal studies that withstand scrutiny and avoid repetition. For executives evaluating pharmaceutical advisory services, the decisive measure is whether a firm can integrate scientific depth, regulatory interpretation and practical CRO oversight into a coherent nonclinical strategy. PreClinical Safety Consultants demonstrates that integration by bridging technical execution with regulatory intent, guiding sponsors from study conception through agency dialogue and helping ensure that nonclinical programs provide a sound foundation for clinical progression.
...Read more
Pharmaceutical Advisor Info
Q1
What led PCS Consultants to be recognized among top pharmaceutical advisory service providers?
PreClinical Safety (PCS) Consultants Ltd has built its reputation in Pharmaceutical Advisory Services through decades of focused expertise in non-clinical drug development. Founded in 1989, it delivers independent scientific advisory services combined with pharmacological and safety evaluations across pharmaceutical and related industries. Its ability to connect early-stage research with clinical development through robust risk–benefit assessments reflects a deep understanding of drug development pathways. This integration of strategy and execution underpins its recognition in Pharmaceutical Advisory Services.
Q2
How does PCS Consultants differentiate its approach to pharmaceutical advisory services?
A senior-expert-led model defines how PCS Consultants delivers Pharmaceutical Advisory Services. Its team consists of highly experienced professionals in pharmacology, toxicology, drug metabolism and regulatory science, many with decades of industry experience. Rather than offering generalized guidance, it provides tailored scientific input aligned with each project’s specific requirements. This emphasis on depth of expertise and individualized strategy ensures that its Pharmaceutical Advisory Services remain both precise and actionable.
Q3
How does PCS Consultants support clients across drug development stages?
End-to-end involvement strengthens PCS Consultants’ Pharmaceutical Advisory Services across the full development lifecycle. It supports early research, non-clinical testing strategy, regulatory documentation and clinical transition planning. The company also collaborates with CROs, designs studies and monitors execution to ensure scientific and regulatory alignment. This comprehensive engagement enables clients to move efficiently from discovery to clinical development with confidence.
Q4
What value do PCS Consultants’ services bring to pharmaceutical development?
Clear decision-making and reduced development risk define the value of its Pharmaceutical Advisory Services. By providing structured scientific input and implementing testing programs, PCS Consultants helps build a reliable foundation for regulatory submissions and clinical progression. Its work ensures that safety data, pharmacological insights and regulatory requirements are aligned, allowing clients to optimize resources and avoid costly delays.
Q5
What role do expertise and regulatory knowledge play in its services?
Regulatory and scientific expertise are central to PCS Consultants’ Pharmaceutical Advisory Services. The company prepares key regulatory documents such as Investigator Brochures, IND submissions and CTDs, ensuring compliance with global standards. Its understanding of international regulatory frameworks and its experience in interacting with authorities allow it to guide clients through complex approval processes with clarity.
Q6
Why is PCS Consultants relevant to current pharmaceutical industry needs?
The growing complexity of drug development and the shortage of senior expertise have increased demand for specialized advisory support, and PCS Consultants addresses this through its Pharmaceutical Advisory Services. Its ability to act as a virtual non-clinical safety department, offering both strategic insight and operational support, aligns with the needs of biotech firms and pharmaceutical companies navigating complex pipelines. This relevance highlights the continued importance of Pharmaceutical Advisory Services in modern drug development.
